American Oncology Network, Inc. (AONC) - Long-Term Debt to Capital

Corporate emblem and logo of American Oncology Network Inc (AONC)

This market valuation chart for American Oncology Network (AONC) illustrates the price action of an asset whose operations rely on managing a network of oncology centers with optimized drug distribution, where the indicator stands at 0.00. The business utilizes third-party contractors for clinic maintenance and cloud-based patient support. Meanwhile, non-clinical tasks are outsourced to external vendors through strict quality protocols, eliminating the organization's technological dependency.

aoncology.com - AONC Long-Term Debt to Capital (period 02/21/2024 - 08/04/2024)
Original product of American Oncology Network

American Oncology Network (AONC) cost optimization through the outsourcing of IT services and logistics requires strict control over its borrowing structure. This metric compares the volume of liabilities with a maturity exceeding one year against the issuer's total equity. This calculation reveals actual financial stability when scaling the business through M&A. The investor determines the balance between default risk and leverage efficiency. The trend of the long-term debt-to-equity coverage ratio confirms the company's strategic reliability.

Key competitors

Long-Term Debt to Equity Ratio BeiGene Ltd. (ONC)|Long-Term Debt to Capital HALO|Long-Term Debt to Capital Revolution Medicines Corp (RVMD)|Long-Term Debt to Equity Ascentage Pharma Group AAPG|CGON: Long-Term Debt to Capital Ratio|UroGen Pharma - Long-Term Debt to Capital|Bicara Therapeutics Inc (BCAX) - Long-Term Debt to Equity Ratio|PSNL: Long-Term Debt to Capital|Long-Term Liabilities to Capital Erasca Oncology (ERAS)|Long-Term Debt to Equity Delcath Systems, Inc.|YMAB: Long-Term Debt to Capital Coefficient|Long-Term Debt to Equity Ratio AURA (Aura Biosciences)|CADL (candeltx.com) - Long-Term Debt to Capital Coefficient|Long-Term Debt to Capital ARAY (Accuray Inc.)|SLS - Long-Term Debt to Equity Ratio|ACTU: Long-Term Debt to Equity Ratio|CTOR - Long-Term Debt to Capital|tuhurabio.com (HURA) - Long-Term Debt to Equity|Protara Therapeutics Inc - Long-Term Debt to Capital Coefficient|FATE (Fate Therapeutics Corp) - Long-Term Debt to Capital|Long-Term Liabilities to Capital Aadi Bio WHWK|Long-Term Debt to Capital TCRX|Long-Term Debt to Capital championsoncology.com (CSBR)|Long-Term Debt to Equity XBiotech XBIT|CVM - Long-Term Debt to Equity Ratio|OS Therapies Inc - Long-Term Debt to Capital|Long-Term Liabilities to Capital Radiopharm Theranostics Ltd|artivabio.com (ARTV) - Long-Term Debt to Equity|Adlai Nortye - Long-Term Debt to Capital Coefficient|VERU (Veru) - Long-Term Debt to Capital|Tempest Therapeutics Inc (TPST) - Ratio of Long-Term Indebtedness to Capital|Long-Term Debt to Capital XLO|Long-Term Debt to Equity Ratio renovarobio.com RENB|Long-Term Debt to Capital MURA (Mural Oncology)|Long-Term Debt to Capital Kairos Pharma Limited KAPA|OKUR - Long-Term Debt to Equity|GDTC (CytoMed Therapeutics) - Long-Term Debt to Capital Ratio|CRIS (curis.com) - Long-Term Debt to Equity Ratio|Apollomics - Long-Term Debt to Capital Coefficient|Long-Term Debt to Equity Tharimmune, Inc.|Long-Term Liabilities to Capital Advanced Biomed Corp ADVB|Long-Term Debt to Equity Genprex (GNPX)|calidibio.com - Long-Term Debt to Capital Ratio|Long-Term Debt to Capital SBFM (Sunshine Biopharma)|XBIO - Long-Term Debt to Equity Ratio|SLRX - Long-Term Debt to Equity|Long-Term Liabilities to Capital purple-biotech.com|BeiGene (BGNE) - Long-Term Debt to Equity|CKPT (Checkpoint Therapeutics Inc.) - Long-Term Debt to Equity|Long-Term Debt to Equity Elevation Oncology, Inc.|Long-Term Liabilities to Capital iCAD Corp ICAD|Long-Term Debt to Capital IKNA|notablelabs.com (NTBL) - Long-Term Indebtedness to Equity|Viracta Therapeutics, Inc. - Long-Term Debt to Equity Ratio|MorphoSys Inc (MOR) - Long-Term Liabilities to Capital|NAYA: Long-Term Debt to Equity Ratio|Long-Term Debt to Capital Coefficient AAPGV (Ascentage)